Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Deepak L. Bhatt(Mount Sinai Hospital), Christie M. Ballantyne(Baylor College of Medicine), Michael Miller(Clark University), Eliot A. Brinton(Inserm), Jean‐Claude Tardif(Montreal Heart Institute), Lixia Jiao(Inserm), Steven Ketchum(Inserm), Rebecca A. Juliano(Inserm), Terry A. Jacobson(Emory University), Philippe Gabríel Steg(Mount Sinai Hospital), Craig Granowitz(Opexa Therapeutics (United States)), Ralph T. Doyle(Inserm)
Cited by 3,238
Related Papers
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
|European Heart Journal|2012|6.8k
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Clinical End Points in Coronary Stent Trials
|Circulation|2007|5.4k